SCHEMBL6827455

SCHEMBL6827455

CC#CCl.c1cc2ccc1-2

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.42
CYP1A1 P04798 1/20 0.42
CYP1B1 Q16678 1/20 0.42
CYP3A4 P08684 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
TAAR1 Q96RJ0 1/20 0.32
HSD17B10 Q99714 1/20 0.32
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32
FFAR1 O14842 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2052 0.76
SCHEMBL3709316 0.71
Chloromethane SCHEMBL28108220 0.71
SCHEMBL2890782 0.71
Iodide SCHEMBL28709938 0.71
Propyne SCHEMBL6278091 0.69
Acetonitrile SCHEMBL6565616 0.69
Ethane SCHEMBL28415154 0.66
SCHEMBL30589936 0.66 ALDH1A1 (0.55) CYP1A2CYP3A4TDP1ALDH1A1TP53
SCHEMBL30135412 0.66 ALDH1A1 (0.55) CYP1A2CYP3A4TDP1ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1119543-B1 N-ARALKYLAMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR ORTHO MCNEIL PHARM INC (US) 2004-12-15 EP disclosed
EP-1119543-A1 N-ARALKYLAMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR Ortho-McNeil Pharmaceutical, Inc. (US) 2001-08-01 EP disclosed
US-6201025-B1 FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ORTHO-MCNEIL PHARMACEUTICAL, INC. 2001-03-13 US disclosed
WO-2000020376-A1 N-ARALKYLAMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2000-04-13 WO disclosed